F. Timar et al., THE ANTIPROLIFERATIVE ACTION OF A MELPHALAN HEXAPEPTIDE WITH COLLAGENASE-CLEAVABLE SITE, Cancer chemotherapy and pharmacology, 41(4), 1998, pp. 292-298
Purpose: The objective of the present study was to examine the relevan
ce of collagenase in the antitumor action of a melphalan peptide (MHP)
with a collagenase-cleavable sequence. The question was addressed as
to whether collagenase may act as an activator or a target in the anti
proliferative mechanism of MI-IF. Methods: Melphalan was inserted into
peptides representing the sequence Pro-Gln-Gly-Ile-Ala.Gly of the col
lagenase-cleavable site iii collagens. Changes in growth and collagena
se IV activities of HT-1080, HT-29, HT-168, and MCF-7 cell cultures we
re investigated. Results: The present investigations provide data indi
cating that Pro-Gln-Gly-Ile-Mel-Gly (melphalan hexapeptide, MHP) is a
substrate for both bacterial and 72-kDa type IV collagenases and that
in this way it can generate Ile-Mel-Gly (melphalan tripeptide. MTP) of
higher cytotoxic potency. Indeed, the formation of MTP was detected i
n the conditioned medium of HT-1080, a collagenase IV-producing human
fibrosarcoma. In a comparison of equimolar concentrations of melphalan
and its two peptide derivatives (MHF and MTP), superior antiprolifera
tive action of MTP was seen in HT-29, HT-1080, and HT-168 tumor cell c
ultures. However, the relatively modest cytostatic actions of MHP were
increased when bacterial collagenase was added to the cell cultures.
After melphalan treatment, reduced levels of both 92 and 72-kDa type I
V collagenases were seen in the HT-1080 cell cultures. However, the re
duction of collagenase activity and the cell counts did not run parall
el in the MTP-or MHP-treated cultures; indeed, collagenase activity re
lated to cell numbers showed an elevated level. Conclusions: As the co
nversion of MHP to the more toxic MTP was detected in the presence of
collagenases, it is possible that collagenase-directed activation of p
rodrugs may be a promising approach for the development of more select
ive cytostatic drugs against malignant tumors with high collagenase ac
tivities.